Hepatic Encephalopathy Management with Lactulose and Rifaximin

Evidence-Based Recommendations

• The American Association for the Study of Liver Diseases recommends lactulose as the first-choice treatment for hepatic encephalopathy, titrated to achieve 2-3 bowel movements per day 1, 2
• Lactulose significantly reduces the risk of recurrent hepatic encephalopathy, with a 14-month recurrence risk of only 20% versus 47% without lactulose 1
• Non-absorbable disaccharides, such as lactulose, have been shown to significantly reduce the risk of recurrent hepatic encephalopathy, with a risk ratio of 0.44 (95% CI: 0.31-0.64) 3

Role of Rifaximin in Hepatic Encephalopathy Management

• Rifaximin is recommended as an adjunct to lactulose for prevention of hepatic encephalopathy recurrence after a second episode of overt hepatic encephalopathy 1, 2
• The European Association for the Study of the Liver suggests that rifaximin should be used in combination with lactulose, as its efficacy as monotherapy is not well established 3

Clinical Evidence Supporting Combination Therapy

• A landmark randomized controlled trial showed that rifaximin added to lactulose decreased the risk of hepatic encephalopathy recurrence to 22.1% versus 45.9% with placebo plus lactulose (hazard ratio 0.42; 95% CI 0.28 to 0.64; p<0.001) 1, 2
• Combination therapy with rifaximin and lactulose showed better recovery from hepatic encephalopathy within 10 days (76% vs. 44%, p=0.004) and shorter hospital stays (5.8 vs. 8.2 days, p=0.001) compared to lactulose alone 4

Dosing Recommendations

• Lactulose should be dosed at 20-30g (30-45 mL) orally 3-4 times daily, titrated to achieve 2-3 soft stools per day 1, 4
• Rifaximin should be dosed at 550 mg twice daily or 400 mg three times daily as an add-on to lactulose 4

Common Pitfalls to Avoid

• Failing to titrate lactulose properly to achieve 2-3 bowel movements daily can lead to treatment failure 1, 3
• Not recognizing and treating precipitating factors for hepatic encephalopathy is essential, regardless of medication choice 2
• Discontinuing therapy after initial improvement is not recommended, as maintenance therapy is needed to prevent recurrence 2

Rifaximin for Hepatic Encephalopathy

Initial Treatment Approach

• The European Association for the Study of the Liver recommends lactulose as the first-line treatment for overt hepatic encephalopathy, dosed at 20-30g (30-45 mL) orally 3-4 times daily, titrated to achieve 2-3 soft bowel movements per day 5

When to Add Rifaximin

• The European Association for the Study of the Liver recommends adding rifaximin 550 mg twice daily as secondary prophylaxis following more than one additional episode of overt hepatic encephalopathy within 6 months of the first episode 5
• Rifaximin should be added when lactulose alone fails to prevent recurrence after a second breakthrough episode 5

Critical Limitations and Pitfalls

• The high cost of rifaximin (approximately $1,500-2,000 per month) may be a significant barrier to routine use, though benefits in reducing hospitalizations may offset costs 6
• In critically ill patients with acute liver failure, there is insufficient evidence to recommend rifaximin 6

Evidence for Mortality Benefit

• Meta-analysis of 19 RCTs (n=1,370) showed rifaximin reduced mortality (RR 0.50; 95% CI 0.31-0.82) and increased recovery from hepatic encephalopathy (RR 0.59; 95% CI 0.46-0.76) 6

Transplant Considerations

• Patients with recurrent or persistent hepatic encephalopathy despite adequate medical treatment should be evaluated for liver transplantation 5
• A first episode of overt hepatic encephalopathy should prompt referral to a transplant center for evaluation 5

Rifaximin Therapy

Primary Indications

• The American Association for the Study of Liver Diseases recommends starting rifaximin 550 mg twice daily as secondary prophylaxis following more than one episode of overt hepatic encephalopathy (HE) within 6 months of the first episode, always in combination with lactulose, with a number needed to treat of 4 for preventing recurrent HE 7
• The European Association for the Study of the Liver suggests that rifaximin plus lactulose reduces HE recurrence from 45.9% to 22.1% (hazard ratio 0.42; 95% CI 0.28-0.64; p<0.001), with 91% of patients on concurrent lactulose therapy 7
• The use of rifaximin monotherapy may only be considered when lactulose is poorly tolerated, though this is based on expert opinion rather than robust evidence, as stated by the Liver International 8

Safety and Efficacy

• The Journal of Hepatology reports that rifaximin can be used safely for long-term continuous therapy (>24 months) with no increased risk of adverse events, and common adverse events in HE patients (10-15%) include peripheral edema, nausea, dizziness, fatigue, and ascites, with rates similar to placebo 7
• The Critical Care Medicine journal notes that rifaximin reduces HE-related hospitalizations (hazard ratio 0.50; 95% CI 0.29-0.87), which may offset costs through reduced hospital admissions 9

Transplant Considerations

• The Journal of Hepatology recommends that a first episode of overt HE should prompt referral to a transplant center for evaluation, and patients with recurrent or persistent HE despite adequate medical treatment (lactulose plus rifaximin) should be considered for liver transplantation 7
• The Gut journal suggests that patients with recurrent or persistent HE despite adequate medical treatment (lactulose plus rifaximin) should be considered for liver transplantation 10

Dosing Summary

Rifaximin Use in Hepatic Encephalopathy

Guideline Recommendations

• The French recommendations suggest rifaximin is not contraindicated in hepatic encephalopathy, although evidence is derived from adult populations 11
• The Critical Care Medicine guidelines do not provide pediatric-specific recommendations for rifaximin use in hepatic encephalopathy, but support its use in adults 12

Efficacy and Safety

• Rifaximin reduces mortality (RR 0.50; 95% CI 0.31-0.82) and increases recovery from hepatic encephalopathy (RR 0.59; 95% CI 0.46-0.76) in adult populations, based on a meta-analysis of 19 RCTs (n=1,370) 12
• There is no formal contraindication to rifaximin use in pediatric hepatic encephalopathy, based on the available literature 13

Secondary Prophylaxis of Overt Hepatic Encephalopathy with Lactulose + Rifaximin

Initial Episode Management

• Start lactulose monotherapy (20–30 g oral, 3–4 times daily) after the first overt hepatic encephalopathy (HE) episode and titrate to achieve 2–3 soft bowel movements per day – AASLD guideline. 14
• Lactulose reduces 14‑month recurrence risk to 20 % versus 47 % without treatment – AASLD guideline. 15
• Continue lactulose indefinitely as secondary prophylaxis after the initial episode – AASLD guideline. 16

When to Add Rifaximin

• Add rifaximin 550 mg twice daily when a patient experiences a second breakthrough overt HE episode while on lactulose (within 6 months of the first episode); continue both drugs indefinitely – AASLD guideline. 17

Efficacy of Combination Therapy (Lactulose + Rifaximin)

• Recurrence of overt HE falls from 45.9 % to 22.1 % with combination therapy (hazard ratio 0.42; 95 % CI 0.28‑0.64; p < 0.001) – AASLD guideline. 15
• Number needed to treat (NNT) = 4 to prevent one recurrent overt HE episode – AASLD guideline. 15
• 91 % of patients in pivotal trials received concurrent lactulose, establishing the combination as the evidence‑based standard – AASLD guideline. 14
• Hospitalization rate reduced from 22.6 % to 13.6 % (NNT = 9) with combination therapy – AASLD guideline. 15

Dosing Algorithm

Sources: AASLD guideline (lactulose dosing) 14; AASLD guideline (rifaximin addition) 15.

Critical Pitfalls to Avoid

• Do not use rifaximin as monotherapy; efficacy is demonstrated only as add‑on to lactulose – AASLD guideline. 16
• Do not add rifaximin after the first overt HE episode; guidelines require a second breakthrough episode – AASLD guideline. 17
• Do not undertitrate lactulose; failure to achieve 2–3 bowel movements daily is a common cause of treatment failure – AASLD guideline. 15
• Do not use rifaximin prophylactically for post‑TIPS HE; neither rifaximin nor lactulose prevents post‑TIPS HE better than placebo – AASLD guideline. 14

Criteria for Discontinuing Prophylactic Therapy

• Discontinue only when all of the following are met:

Liver Transplantation Referral

• Refer to a transplant center after the first overt HE episode for evaluation – AASLD guideline. 18
• Consider transplantation for patients with recurrent or persistent HE despite optimal lactulose + rifaximin therapy – AASLD guideline. 18

Secondary Prophylaxis of Overt Hepatic Encephalopathy in Cirrhosis: Lactulose ± Rifaximin Strategy

Initial Lactulose Therapy

• Begin lactulose 20–30 g orally 3–4 times daily immediately after the first overt hepatic encephalopathy (HE) episode, titrating to achieve 2–3 soft bowel movements per day and continuing indefinitely as secondary prophylaxis. 19

Criteria for Adding Rifaximin

• Do not introduce rifaximin after the first overt HE episode; add rifaximin 550 mg orally twice daily only after a second breakthrough overt HE episode occurs while the patient is on lactulose (typically within 6 months of the first episode). 19

Evidence Supporting Combination Therapy

• In the pivotal rifaximin trial, 91 % of participants received concurrent lactulose, establishing the lactulose + rifaximin combination as the evidence‑based standard for secondary prophylaxis rather than rifaximin monotherapy. 19
• Rifaximin monotherapy is not recommended for initial treatment of overt HE because randomized controlled trials provide insufficient evidence to support its use alone. 19
• Rifaximin may be considered as monotherapy only when lactulose is poorly tolerated; this recommendation is based on expert opinion rather than robust trial data. 19

Safety Profile in Cirrhosis

• Long‑term continuous rifaximin therapy (> 24 months) does not increase the risk of adverse events, bacterial resistance, or Clostridioides difficile infection in patients with cirrhosis. 19

Monitoring and Management of Recurrence

• If overt HE recurs despite optimal lactulose dosing, verify patient adherence to lactulose before adding rifaximin. 19
• Regardless of pharmacologic therapy, always identify and treat precipitating factors (e.g., infections, gastrointestinal bleeding, electrolyte disturbances, constipation, offending medications). 19

Dosing Algorithm

All treatment recommendations above are based on the evidence cited in Liver International (2023). 19